Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00342771 · ClinicalTrials.gov registry record

An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
2,033
Enrollment target

NCT00342771: Completed study, sponsored by National Cancer Institute (NCI).

NCT00342771 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,033 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00342771 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
2,033 participants
Enrollment target

Study Summary

This study will examine the association of genetic variants and gene expression patterns with the risk of prostate cancer. There will be (It will include?) genotype analysis of blood DNA from 600 patients with the disease and from 600 healthy people, and there will be a gene expression analysis of prostate tumors. Prostate cancer is a leading cause of death among men in Western countries. It is estimated that 220,000 or more new cases of the disease will occur in the United States during 2004. The disease incidence is rising. About 25% to 30% of the cancers become aggressive. The nonhereditary disease rarely occurs in men who are younger than age 40. There are large differences in incidence by geography and race. The highest rates are seen among African-American men in the United States. Also, although Caucasians have a lower rate of disease incidence and mortality in the United States, the rates among them are high compared with rates in some European countries. The reasons for such differences are not well understood, but both environmental and genetic risk factors are thought to be involved. Patients ages 40 to 80 years who have had prostate cancer confirmed within the past 6 months, who reside in Baltimore City or adjacent metropolitan counties, and who were born in the United States may be eligible for this study. They will be recruited in collaboration with the Departments of Pathology and Urology at the University of Maryland and the Baltimore Veterans Affairs Medical Center. Those men serving as controls in this study will be identified through the Department of Motor Vehicles database and will be matched by age and race with the patients who have cancer. The study will include 600 participants with prostate cancer and 600 participants in the control group. Trained interviewers will administer two questionnaires. The primary questionnaire will be used to assess information such as medical and cancer history, tobacco use, current medications, occupational h

Trial Details

FieldValue
Enrollment Target 2,033 participants
Start Date 2004-11-08
Est. Completion 2020-08-06

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00342771

The ClinicalTrials.gov registry entry for NCT00342771 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,033 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00342771 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00342771 about?

NCT00342771 is a clinical study titled "An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males". This study will examine the association of genetic variants and gene expression patterns with the risk of prostate cancer. There will be (It will include?) genotype analysis of blood DNA from 600 patients with the disease and from 600 healthy people, and there will be a gene expression analysis of p...

What is the current status of trial NCT00342771?

This trial is currently completed. The enrollment target is 2,033 participants. The study started on 2004-11-08. Estimated completion is 2020-08-06.

Who is sponsoring clinical trial NCT00342771?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.